Summary
Rationale: The spread of foam sclerotherapy has resulted in the renaissance of sclerotherapy as a non-invasive treatment method for varicosis.An expanded European expert committee meeting in Tegernsee in April 2006 was prompted by new findings and continuous further development of the method and worked especially on the topics "The role of (duplex) ultrasound in Foam sclerotherapy" and "Evaluation of therapeutic effects of foam Sclerotherapy". It was felt that these criteria are "non-specific"to foam sclerotherapy and would possibly also be suitable for other endovenous ablative procedures. The organisers of the 2 nd European Consensus Meeting on foam sclerotherapy (2 nd ECMFS) were then asked to publish these recommendations in this separate publication. The entire recommendations of the 2 nd ECMFS are published in an extensive overview in this journal (VASA 2008; 37; Supplement 71: 1-32). Methodology: The 29 participants were sent a comprehensive questionnaire in advance covering all the relevant aspects of foam sclerotherapy. The organisers drew up various preliminary statements on the basis of the results. During the meeting itself the participants revised and/or approved and/or rejected these statements. For the "non-specific" topics, two working groups were given the task of conducting the concluding assessment of these items.Their final results were presented in March and April 2007. Results: For foam sclerotherapy, duplex ultrasound is important in pre-treatment diagnosis, treatment monitoring/guidance, post-treatment efficacy evaluation and surveillance. In the pre-treatment diagnosis of varicose veins, the exact localisation of the insufficient saphenous, communicating and perforating veins is important. Duplex ultrasound is the accepted gold standard for this purpose. The application of ultrasound imaging during foam sclerotherapy increases the safety of accessing the vein in certain indications, and it can help when making a decision concerning the foam volumes to be injected, the patients' position or specific movements the patients should perform. Following treatment, the findings of duplex ultrasound, the clinical findings and the patients' symptoms can be arranged according to the recommended definitions. This allows grading of the therapeutic outcome and enables a better comparability between different treatment protocols or different treatments. Besides the evaluation of treatment success, duplex ultrasound is the method of choice to exclude or confirm complications such as deep venous thrombosis or disease progression. 
Zusammenfassung

Introduction
The spread of foam sclerotherapy has resulted in the renaissance of sclerotherapy as a treatment method for varicosis [4] . The correct use of sclerosant foam for the right indications for various forms of varicosis has now become established world-wide as safe and effective. The joint recommendations for indications, treatment and follow-up drawn up by European experts in this field at the 1 st European Consensus Meeting on Foam Sclerotherapy (1 st ECMFS) in 2003 [1] were possibly able to contribute to this. The results helped to introduce a certain systematic approach to patient selection and treatment. However, while the criteria for the evaluation of the efficacy of the procedure were already addressed that time, they were not discussed in too much detail. In published literature there are no generally accepted variables to decide whether or not a treatment may be judged as "successful". A 2 nd European Consensus Meeting on Foam Sclerotherapy (2 nd ECMFS) was held by an expanded European expert committee in Tegernsee, Germany, in April 2006, prompted by new findings and the continuous further development of foam sclerotherapy [2] . Experts in foam sclerotherapy were asked to contribute to this meeting if they had published or presented data, participated in clinical trials, or had otherwise scientifically or medically contributed to Foam Sclerotherapy. It became clear during this meeting that the use of ultrasound and the evaluation of treatment efficacy have to be seen as an integral part of the procedure.Since efficacy criteria vary considerably in published data, much emphasis was put on defining the clinical and technical criteria for evaluating treatment success. Appropriate times for evaluating these were also discussed. The resulting recommendations were systematically compiled, discussed and "negotiated", and were finally considered adequate by the participants and subsequent working groups. Thus, they take into account the currently available experience, opinions and scientific knowledge of the participants at the meeting. It was felt that these criteria are "nonspecific" to foam sclerotherapy and would possibly be suitable for other endovenous ablative procedures as well.The organisers of the 2 nd ECMFS were asked to publish the "non-specific" recommendations "The role of (duplex) ultrasound in foam sclerotherapy" and "Evaluation of therapeutic effects of foam sclerotherapy" in this separate publication. The entire recommendations of the 2 nd European Consensus Meeting on Foam Sclerotherapy are published in an extensive overview (VASA 2008; 37; Supplement 71: 1-32).
Methodology
29 experts in the field of foam sclerotherapy were requested to comment on the recommendations of the 1 st ECMFS 2003 and to urge discussion on topics that had received little if any attention to date. Evaluation of this first questionnaire led to the preparation of a second, more extensive questionnaire, dealing with a number of different topics, including personal experience, treated indications, methods of sclerosant foam preparation, sclerosant concentrations used, foam volumes injected and more. In addition, the questionnaire asked about the criteria for evaluating the efficacy of foam sclerotherapy and about the role of (duplex) ultrasound in this procedure. Beginning in March 2006, the organisers prepared approximately 100 provisional "statements" on the basis of the processed data."Consensuses" were prepared providing that all -or almost all -of the participants had given the same or at least very similar answers to the questions. In the case of only absolute or simple majorities, responses concurring less obviously, or a low number of answers, "descriptions" of the responses were prepared. Each statement was presented to the participants during the meeting itself in April 2006 and was discussed in depth. The participants were able to adopt, modify or even reject any of the "Consensuses" or "Descriptions". Following the discussions at the 2 nd ECMFS, two working groups were given the task of conducting the concluding assessment of the items "The role of (duplex) ultrasound in foam sclerotherapy" and "Efficacy evaluation of foam sclerotherapy". Both items are closely linked, and (duplex) ultrasound has additional impact on safety aspects during and after the treatment. The working groups spent several weeks working on the final wording of the individual recommendations and presented their final results in March and April 2007 to be voted on.
Results
The Role of (duplex) ultrasound in foam sclerotherapy Duplex ultrasound is important in pre-treatment diagnosis, treatment monitoring/guidance, post-treatment efficacy evaluation and surveillance. In the pre-treatment diagnosis of varicose veins, the exact localisation of the insufficient saphenous, communicating and perforating veins is very important. Duplex ultrasound is the accepted gold standard for this purpose [3, 6] . The ultrasound guidance of venepuncture is thought to be very important by a majority of the par- February 2008 ticipants. It helps to confirm the intravascular placement of needles, catheter tips or any other means of vein access. Also, the injected foam can be visualised by ultrasound. It was decided by all but one expert that ultrasound guidance during the puncture and injection of non-visible varicose veins is mandatory, as specified in more detail in Consensus 1. Besides other procedures,ultrasound amounts) are seen in the deep venous system. If large amounts are seen in the deep venous system, muscle activation has been recommended to clear the vessels of any substances with possible sclerosing properties [5] . Frequently, but not always, with ultrasound imaging vasospasm can be detected shortly following the injection of sclerosant foam. Published literature provides data about the frequency of vasospasm after foam injection and about the positive predictive value of vasospasm concerning short-term treatment success [8] . In another multicentre randomised clinical trial, the decision to re-inject sclerosant foam at the same session was based on the onset of vasospasm after the preceding injection in order to minimise the total foam volume [7] . For a slight majority of the participants, the occurrence of vasospasm of the injected vein is an indicator for the "immediate" efficacy of foam injection. On the other hand, several experts have also made the experience that a vein could re-open despite the occurrence of vasospasm (and despite "immediate" or "shortterm"success). Therefore, the majority of participants felt that the occurrence of vasospasm of the injected vein was not an indicator for a (finally) sufficient foam volume or for a sufficient foam concentration. In other words, vasospasm only shows that the vein has been affected by the foam, irrespective of whether or not the volume and concentration have been sufficient to ensure a finally successful outcome. To conclude, the use of ultrasound imaging during foam sclerotherapy increases the safety of accessing the vein in certain indications, and it can help when making a decision concerning the foam volumes to be injected, the patients' position or specific movements the patients should perform. A documentation of the results is, of course, possible, too.
Evaluation of the therapeutic effects of foam sclerotherapy
The easiest way of assessing the therapeutic effects of foam sclerotherapy is by clinical evaluation and according to changes in patients'symptoms. Irrespective of the modality of the 
Consensus 3: Evaluation of the therapeutic effects of foam sclerotherapy
The therapeutic effects of foam sclerotherapy in a patient's limb should be evaluated clinically and according to the patients' symptoms. The effects of foam sclerotherapy in GSV, SSV, tributaries, recurrent varicose veins, perforating veins and venous vascular malformations should also be evaluated by duplex ultrasound.
imaging helps to increase safety during injection. With ultrasound imaging, it can be monitored whether foam is reaching the region intended to be treated (e.g. sapheno-femoral junction). It can also be visualised whether relevant amounts of foam are reaching regions not intended to be treated (e.g. muscle veins, deep veins). With ultrasound imaging, small echogenic structures (bubbles) are frequently seen in the deep venous system soon after the injection of sclerosant foam. It is believed that, after a short time, the foam bubbles turn into gas bubbles without an active sclerosant coating, i.e. without a sclerosant effect. Routinely performed muscle activation to flush away these bubbles is maybe not necessary if single bubbles (i.e. small clinical and technical assessment of any therapeutic effect, the optimum timeframe for this assessment should enabling a better comparability between different treatment protocols or different treatments. The question, in which patients reinjection is necessary or useful, following the grading of Consensus 7, was discussed but could not be answered during the 2 nd ECMFS. There are no reliable data to answer this question at present. On the other hand, the experts made clear during the discussions that patients with a grading 2a or 2b would hardly be reinjected, and that in patients with grading 2c re-injection would sometimes be done. The natural development of "partially successfully"treated veins (grading 1) is not clear: they could re-open completely, become occluded over the course of time, or remain "partially successful", with or without re-injection. In these patients, re-injection often depends on the clinical situation or on the symptoms, and in most of the cases most of the experts would re-inject. In published literature, it has been shown that the rate of successful treatments after ultrasound-guided foam sclerotherapy can be increased if re-injection is performed in re-opened veins after initial treatment success or in non-occluded veins after the first treatment ("secondary success") [9] . In patients with grading 0, there is a clear indication for re-treatment.
If re-treatment is done, the majority repeat the injections with the same or a lower volume of sclerosant foam of a higher concentration, and some participants repeat the treatment with higher volumes of foam made from a higher concentration. Besides evaluation of the treatment success, duplex ultrasound is the method of choice to exclude or confirm complications such as deep venous thrombosis or disease progression.
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